-71.1%
CIFR vs MRNA
+945.0%
-1,016.1%
-77.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -20.0% | +13.1% | -33.1% | -20.3% |
| 7D | -26.7% | +20.6% | -47.4% | -27.2% |
| 30D | -58.0% | +27.1% | -85.2% | -58.3% |
| 3M | -68.1% | +353.4% | -421.5% | -71.2% |
| 6M | -63.7% | +446.3% | -509.9% | -70.3% |
| YTD | -56.0% | +776.2% | -832.1% | -69.5% |
| 1Y | -71.1% | +987.9% | -1,059.0% | -81.4% |
| All | -71.1% | +945.0% | -1,016.1% | -81.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling